Real-world data on the efficacy and safety of daratumumab treatment in Hungarian relapsed/refractory multiple myeloma patients by Lovas, Szilvia et al.
Vol.:(0123456789) 
International Journal of Hematology 
https://doi.org/10.1007/s12185-019-02715-w
ORIGINAL ARTICLE
Real‑world data on the efficacy and safety of daratumumab treatment 
in Hungarian relapsed/refractory multiple myeloma patients
Szilvia Lovas1 · Gergely Varga2 · Péter Farkas2 · Tamás Masszi2 · Nikolett Wohner2 · Ágnes Bereczki3 · 
Nóra Adamkovich3 · Zita Borbényi3 · Árpád Szomor4 · Hussain Alizadeh4 · Erika Szaleczky5 · Krisztina Wolf5 · 
Tamás Schneider5 · Márk Plander6 · Tamás Szendrei6 · Ottó Csacsovszki7 · Zoltán Csukly7 · Péter Rajnics8 · 
Miklós Egyed8 · Zsolt Nagy9 · László Rejtő10 · Árpád Illés1 · Gábor Mikala7 · László Váróczy1 
Received: 8 May 2019 / Revised: 2 August 2019 / Accepted: 2 August 2019 
© Japanese Society of Hematology 2019
Abstract
Daratumumab is a human anti-CD38 monoclonal antibody used in the treatment of refractory and relapsed multiple myeloma. 
We investigated the efficacy and safety of daratumumab therapy in a real-world setting. Ninety-nine Hungarian patients 
were included; 48 received monotherapy, while lenalidomide and bortezomib combinations were administered in 29 and 19 
cases, respectively. Overall response rate was assessable in 88 patients, with 12 complete, 10 very good partial, 34 partial, 
and seven minor responses. At a median duration of follow-up of 18.6 months, median progression-free survival (PFS) 
among all patients was 17.0 months. These values were inferior in the bortezomib combination and monotherapy groups. 
Patients with early-stage disease (ISS1) had better survival results than those with stage 2 or 3 myeloma (p = 0.009). Heavily 
pretreated patients had inferior PFS compared to those with 1–3 therapies (p = 0.035). Patients with impaired renal function 
had PFS results comparable with those having no kidney involvement. There were 10 fatal infections, and the most frequent 
adverse events were mild infusion-associated reactions and hematologic toxicities. Our results confirm that daratumumab 
is an effective treatment option for relapsed/refractory MM with an acceptable safety profile in patients with normal and 
impaired renal function.
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Introduction
Multiple myeloma (MM) is a malignant hematologic dis-
order that accounts for one percent of all cancer cases. It 
can be characterized by clonal proliferation of plasma 
cells; its main complications include the development of Gábor Mikala and László Váróczy equally contributed to this 
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lytic bone lesions, hypercalcaemia, bone marrow failure, 
and renal impairment. It is considered as an incurable dis-
ease; however, there has been a significant improvement 
in patients’ survival, thanks to the novel drugs that have 
been recently introduced [1]. Besides immunomodulatory 
drugs (IMID) and proteasome inhibitors (PI), monoclonal 
antibodies (moAB) have also become available for the treat-
ment of refractory–relapsing cases. One of the important 
antibody targets in MM is CD38 that is highly expressed on 
plasma cells. However, CD38 can be also detected on the 
surface of NK-cells, activated T cells, B cells, erythrocytes, 
and platelets [2]. Daratumumab is a first-in-class, human 
immunoglobulin G1 kappa (IgG1κ) monoclonal antibody 
that targets CD38 and kills plasma cells through antibody-
dependent cellular cytotoxicity- and complement-dependent 
cytotoxicity-mediated mechanisms [3]. In addition to these 
immune-mediated killing processes, daratumumab may also 
have an immunomodulatory role via T cell activation and 
expansion as well as moderation of immunosuppression. The 
anti-tumor efficacy of daratumumab can be increased by the 
addition of immunomodulatory drugs. Lenalidomide can 
facilitate antibody-mediated lysis of plasma cells by activat-
ing autologous effector cells within the natural environment 
of the tumor [4]. This conclusion was confirmed by another 
study where daratumumab was combined with lenalidomide 
and bortezomib [5].
Currently, daratumumab is one of the most effective 
new agents lately approved for relapsed/refractory multiple 
myeloma (RRMM), first in monotherapy in massively pre-
treated patients, later in triplet combinations from the first 
relapse. Although clinical trials showed good tolerability 
and high effectivity of daratumumab both in monotherapy 
and as combined with lenalidomide or bortezomib, trials 
are different from real-world use for many reasons including 
less rigorous patient selection, greater flexibility with dosing 
and combinations, and also country-specific funding restric-
tions making real-world data very important for clinicians. 
In terms of daratumumab, the registration studies limited the 
inclusion to patients with normal or only moderately altered 
renal function and real-world data regarding daratumumab 
use in patients with renal failure is currently very limited.
The aim of this study was to evaluate the efficacy and 
safety of daratumumab-based therapies in a large cohort of 
Hungarian relapsed/refractory MM patients.
Patients, procedures, and methods
We approached all centers in Hungary where daratumumab 
was used, in a retrospective data collection. The clinical files 
of multiple myeloma patients were reviewed with particular 
reference to age, sex, clinical stage, renal function, response 
to treatment and survival. ISS stages were determined using 
the International Myeloma Working Group (IMWG) criteria. 
The way how FISH testing was performed varied, there was 
no consensus regarding the probes used but those for 17p 
deletion, translocations (11;14), (4;14) and (14;16), and 1q 
amplification were generally part of the set. FISH results 
of unfavorable prognosis included t(4;14), t(14;16), and 
del(17p).
Patients received daratumumab in the dose of 16 mg/kg 
intravenously once weekly in the first 8 weeks, than 16 mg/
kg every second week (lenalidomide arm) or 16 mg/kg every 
third week (bortezomib arm) for 12 weeks and finally 16 mg/
kg every 4 weeks. 20 mg dexamethasone was given orally or 
intravenously on days 1, 2, 4, 5, 8, 9, 11, and 12. Bortezomib 
was administered at doses varying from 1 to 1.3 mg/m2 on 
days 1, 4, 8, 11 or only on days 1 and 8, while lenalidomide 
was given at doses of 10–25 mg on days 1–21. Response 
criteria (complete response [CR], very good partial response 
[VGPR], partial response [PR], no response [NR], and pro-
gressive disease [PD]) and survival measures (progression-
free survival [PFS] and overall survival [OS]) were defined 
according to the published IMWG guidelines. Examining 
the survival rates, overall survival (OS) was determined 
by consideration of death events due to any reasons, while 
progression-free survival (PFS) was determined by consid-
eration of relapses, death events or disease progression that 
indicated further treatment. Survival rates were calculated 
using the Kaplan–Meier’s method, while the survival data 
were compared using the log-rank test. Differences were 
significant if probability level was less than 5% (p < 0.05).
Results
Patient characteristics
Ten centers responded with 99 patients altogether, who were 
treated with daratumumab-based therapies between Septem-
ber 2016 and December 2018. Patient demographics were 
generally balanced. 51.1% of the patients were male. Aver-
age age was 60.3 ± 10.7 (median: 62; range 28–84). Patients 
were heavily pretreated, the median number of prior lines 
was 3 (range 1–12). Almost all patients had prior bortezomib 
(97%) and most had lenalidomide (77.8%) and thalidomide 
(82.8%), all but one had one of the two IMiDs. 62.6% of 
the patients had prior autologous transplantation, two prior 
allograft as well. Pre-daratumumab cytogenetic FISH tests 
of 63 patients were available, and here 36 (57.1%) had high 
risk cytogenetics. The majority had high International Stag-
ing System (ISS) Score: 20, 19, and 60 were in the ISS 1, 
2, and 3 groups, respectively. Treatment usually continued 
until progression, unacceptable toxicity or death, the median 
number of cycles was 5. Markedly impaired renal function 
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(GFR < 30 ml/min) has been reported in 11 cases, including 
6 patients who required hemodialysis (Table 1).
Adverse events
According to the reported number of adverse events (AEs), 
daratumumab treatment was well tolerated. AEs above grade 
1–2 were rare. The most frequent AEs were mild infusion-
associated reactions (IARs, grade 1–2), hematologic toxici-
ties (mostly neutropenia), and infections.
There were ten fatal infections that included 6 cases with 
septicaemia and 4 cases with bronchopneumonia. Other fatal 
AEs were absent. Infusion-related toxicities were manage-
able in all cases (Table 2).
Efficacy
The majority of patients (48 cases, 48.9%) had mono-
therapy with dexamethasone only, but 19 of them (19.3%) 
had bortezomib and 29 of them (29.3%) received lena-
lidomide in combination. In three cases, daratumumab 
was combined with other agents (carfilzomib or cyclo-
phosphamide). Patients who received only daratumumab 
monotherapy underwent more prior treatment lines than 
those who received combinations with lenalidomide and 
dexamethasone (DRd) or bortezomib and dexamethasone 
(DVd); the mean values were 4.13 ± 2.017, 3.58 ± 2.23, 
and 2.77 ± 0.869, respectively. Overall response rate was 
assessable in 88 patients with 12 complete, 10 very good 
partial, 34 partial, 7 minor responses. 25 showed progres-
sive disease. 9 patients had no formal disease reassess-
ment due to either early death or short follow-up. Those 
patients who received either bortezomib or lenalidomide 
combinations showed significantly better overall response 
rates than those who had monotherapy (p < 0.001) (Fig. 1).
The clinical cutoff date was December 31, 2018. At 
a median duration of follow-up of 18.6 months (range 
1–27.5), the median PFS was 17.0 months in the whole 
cohort. There was a trend of inferior PFS in the borte-
zomib combination and monotherapy groups (6.6 months 
in both), while median PFS was not reached in the lena-
lidomide group (Fig. 2). Patients having an early-stage 
disease (ISS1) had significantly better survival results 
than those who had stage 2 or 3 myeloma (Fig. 3). The 
number of prior therapies seemed to be another impor-
tant prognostic marker as extensively pretreated patients 
who received more than 3 treatment lines had inferior PFS 
data (Fig. 4). In terms of the FISH results, patients hav-
ing adverse genetic alterations showed markedly inferior 
survival in comparison with standard FISH results (post 
hoc analysis, p = 0.049) (Fig. 5). Interestingly, patients 
with markedly impaired renal function had comparable 
PFS results to those having no kidney dysfunction (Fig. 6).
Table 1  Clinical characteristics of patients
Characteristics
Age at the diagnosis, years
 Median (range) 62 (28–84)
 Distribution, n
  < 65 62
  65–74 31
  75≤ 6
Median time from diagnosis, years (range) 4 (0–27)
Type of measurable disease, n (%)
 IgG 53 (53.5)
 IgA 19 (19.2)
 Light chain 27 (27.3)
ISS disease staging, n (%)
 I 20 (20.2)
 II 19 (19.2)
 III 60 (60.6)
Number of prior lines of therapy (%)
 Median (range) 3 (1–12)
 1–3 43 (43.4)
 > 3 56 (56.6)
Prior treatments, n (%)
 Bortezomib 96 (97)
 Thalidomide 82 (82.8)
 Lenalidomide 77 (77.8)
 Prior ASCT, n (%) 61 (62.6)
Pre-daratumumab cytogenetic profile, n (%)
 Standard-risk cytogenetic abnormality 17/63 (27)
 High-risk cytogenetic abnormality 36/63 (57.1)
  dell 7p 7/63 (11.1)
  t(4,14) 8/63 (12.7)
  t(14,16) 2/63 (3.2)
  Other 10/63 (15.9)
Renal function, n (%)
 Normal or slightly impaired (GFR > 30 ml/min) 88 (88.8)
 Markedly impaired (GFR < 30 ml/min) 11 (11.1)
Table 2  Side effects of daratumumab-based therapies
Grade 1–2 Grade 3 Grade 4 Grade 5
Infusion-associated reaction 15 1
Neutropenia 5 2
Anemia 1 2
Thrombocytopenia 2 1
Infection 3 4 1 10
Cardiovascular 1
Gastroenterology 2
Neurology 1 1
All 27 11 4 10
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Discussion
Daratumumab has been recently approved for the treat-
ment of RR multiple myeloma patients. As the first moAB 
therapy in MM, it has potent single-agent activity, as it 
was revealed by the GEN501 and SIRIUS trials. Pooled 
analysis of these studies showed an overall response rate of 
31.1%, a median PFS of 4 months, and OS of 20.1 months 
in RR MM patients with a median of five prior lines of 
therapy [6, 7]. Later on, there were two pivotal clinical 
trials conducted, where daratumumab showed its unique 
efficacy in combination therapies as well. In the CASTOR 
trial, daratumumab plus bortezomib and dexamethasone 
(DVd) treatment was administered for RR MM patients, 
while bortezomib and dexamethasone were given on 
the control arm. After 19.4 months of median follow-
up, patients receiving daratumumab-based combination 
showed significantly more favorable overall response 
rates (83.8% vs. 63.2%, p < 0.0001) and progression-free 
Fig. 1  Therapeutic responses 
after daratumumab monother-
apy, bortezomib and lenalido-
mide combinations
Fig. 2  Progression-free survival 
in terms of combination regi-
mens
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survival (median 16.7 vs. 7.1 months, p < 0.0001) than 
those being randomized to the control arm. Daratumumab 
plus bortezomib and dexamethasone was superior in sub-
groups based on treatment exposure, lenalidomide-refrac-
tory status or cytogenetic status [8, 9]. In the POLLUX 
trial, patients received either daratumumab plus lena-
lidomide and dexamethasone (DRd) therapy or lenalido-
mide and dexamethasone (Len/Dex) combination. After 
25.4 months of median follow-up, the DRd treatment pro-
longed progression-free survival vs. Len/Dex (median not 
reached vs. 17.5 months, p < 0.0001). The overall response 
rate was 92.9% vs. 76.4%, and 51.2% vs. 21.0% achieved 
a complete response (p < 0.0001). Analyses of clinically 
relevant patient subgroups demonstrated that PFS results 
were favorable for the daratumumab arm even within 
bortezomib-refractory patients, within those with previ-
ous lenalidomide exposure or within those with adverse 
FISH results [10, 11].
There are only a limited number of publications available 
in terms of real-world results of daratumumab treatment. 
Minarik et al. reported on 14 RR MM patients who received 
daratumumab monotherapy after a median 4.5 previous 
lines. The overall response rate was 38.5%. The median 
progression-free survival was 4.6 months and median overall 
survival was not achieved. The toxicities were mostly mild 
[12]. A French group reported the results of a single-center 
series of 41 RRMM patients treated with single-agent dara-
tumumab outside clinical trials. Patients received a median 
number of 4 prior therapies. All patients were previously 
exposed to PI and IMID and all patients were refractory to 
Fig. 3  Progression-free survival 
in terms of ISS stages
Fig. 4  Progression-free survival 
in terms of the number of previ-
ous treatment lines
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the last line of therapy. The overall response rate was 24%; 
however, after a median follow-up of 6.5 months, all patients 
experienced disease relapse. The median progression-free 
survival was only 1.9 months [13].
In Hungary, ninety-nine RR multiple myeloma patients 
received daratumumab therapy outside any clinical tri-
als until December 2018. Our treatment protocols were 
strongly influenced by funding rules of the National Health 
Insurance, since daratumumab had been reimbursed only as 
monotherapy for patients who received over 3 prior lines of 
treatment until June 2017 and then it became available as a 
part of combination therapy for patients who received > 2 
prior treatment modalities. As a result, most of our patients 
were heavily pretreated and received only daratumumab 
monotherapy. Their treatment responses and survival results 
were still comparable to the data of the SIRIUS trial. How-
ever, those patients who received either bortezomib or lena-
lidomide combination therapies showed inferior treatment 
and survival results compared to the data known from the 
CASTOR and POLLUX trials. This can be explained by 
the fact that our patients came from the “real world” and no 
strict exclusion criteria were applied regarding the complete 
blood count, renal function, and ECOG status. Moreover, we 
treated much less 2nd and 3rd line patients who dominated 
the POLLUX and CASTOR trials [14].
Analyzing the data of relevant subgroups, we detected 
that ISS and the number of prior therapies were the most 
important predictive factors in terms of the survival results. 
Patients having adverse genetic alterations showed mark-
edly inferior survival compared to those with standard FISH 
Fig. 5  Progression-free survival 
in terms of FISH results
Fig. 6  Progression-free survival 
in terms of renal function
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results. Interestingly, patients with impaired renal function 
showed similar PFS results to those who had normal GFR 
values. As this population was excluded from the POLLUX 
and CASTOR trials, we are the first to demonstrate that dara-
tumumab can be safely administered for MM patients with 
renal failure, including those on dialysis.
Serious adverse events including patients’ deaths 
occurred in 14 cases (14.1%) which rate is also higher than 
those observed in the official clinical trials. Fortunately, 
most of our patients developed no or only minor side effects.
We confirmed in a real-world setting that daratumumab 
is an effective treatment option for relapsed/refractory MM 
with acceptable safety profile; however, not surprisingly, our 
treatment results and survival data were inferior to the data 
of selected patients of official clinical trials. Our study is 
the first one that reports real-world results of daratumumab 
treatment in the settings of monotherapy and combinations 
as well. Moreover, we are the first to demonstrate that dara-
tumumab can be safely used in a large cohort of patients 
with GFR < 30 ml/min.
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